Second, platinum-based chemotherapy was widely applied in NSCLC, and the reduced uptake of platinum resulting from SLC31A1 downregulation could reduce drug sensitivities and clinical outcomes. This evidence concerns the gene SLC31A1 and non-small cell lung carcinoma.